Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Delayed initial recovery and long lie following a fall among middle-aged and older adults with multiple sclerosis.
Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.
HMG-CoA reductase inhibitor simvastatin inhibits proinflammatory cytokine production from murine mast cells.
Cannabinoids decrease the th17 inflammatory autoimmune phenotype.
Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies.
Combined use of pharmacophoric models together with drug metabolism and genotoxicity "in silico" studies in the hit finding process.
Clinical predictors of an optimal response to natalizumab in multiple sclerosis.
Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system.
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.
The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis.
Involvement of ER Stress in Dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 Missense Mutations Shown by iPSC-Derived Oligodendrocytes.
What is microglia neurotoxicity (Not)?
Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure.
Vm24, a Natural Immunosuppressant Peptide Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells.
The effects of heat stress on physical functioning in persons with multiple sclerosis.
Predictors of driving in individuals with relapsing-remitting multiple sclerosis.
Stiffness as a presenting symptom of an odd clinical condition caused by multiple sclerosis and myotonia congenita.
Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.
Cognitive correlates of under-ambiguity and under-risk decision making in high-functioning patients with relapsing remitting multiple sclerosis.
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
Preliminary Investigation of Gait Initiation and Falls in Multiple Sclerosis.
Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis.
Moral Distress: Recognition, Diagnosis, and Treatment.
Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis.
Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: an open label study.
Pages
« first
‹ previous
…
287
288
289
290
291
292
293
294
295
…
next ›
last »